TEC Says More Evidence Is Required To Judge AMD Combination Therapies
This article was originally published in The Gray Sheet
Executive Summary
More data are needed before healthcare experts can assess the potential benefits of combining new drugs with photodynamic therapy to treat age-related macular degeneration (AMD), according to BlueCross BlueShield Association's Technology Evaluation Center
You may also be interested in...
MCAC Advises AMD Manufacturers To Conduct Randomized, Controlled Trials
Manufacturers developing treatments for age-related macular degeneration (AMD) should conduct randomized, controlled trials, CMS' Medicare Coverage Advisory Committee recommended at a Nov. 29 meeting in Baltimore
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.